Speeding the Weaning up: Aggressive Screening Criteria and Higher Minimal Ventilatory Settings.
Launched by GONZALO HERNANDEZ MARTINEZ · Feb 16, 2021
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
Discontinuation of mechanical ventilation is a three-step process including:
1. - Readiness testing.
It evaluates the criteria to determine whether a patient might be able to be successfully and safety weaned from mechanical ventilation. The detection of readiness to try a spontaneous breathing test has controversial questions, in special concerning to oxygenation. From a conservative to an aggressive criteria we can list:
1. PaO2/FiO2 \> 200 on PEEP ≤ 5 cm H2O (Esteban et al, 1999).
2. PaO2/FiO2 ≥ 150 on PEEP ≤ 8 cm H2O (Boles et al, 2007).
3. PaO2/FiO2 \> 180 on PEEP ≤ 10 cm...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients on mechanical ventilation for more than 24 hours with \>= positive end-expiratory pressure 10.
- • Patients with up to three high risk factors for extubation failure excluding hypercapnia during the spontaneous breathing trial and obese patients (BMI \>30).
- • Patients fulfilling weaning criteria expected to have a spontaneous breathing trial in the following 24 hours.
- • Patients expected to be prevented with high-flow oxygen therapy after extubation.
- Exclusion Criteria:
- • \<18 years old.
- • Pregnant women.
- • Tracheostomized patients.
- • Accidental or self-extubated patients.
- • Obese (BMI \>30) or hypercapnic patients during the spontaneous breathing trial.
About Gonzalo Hernandez Martinez
Gonzalo Hernandez Martinez is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong emphasis on innovation and ethical practices, the organization collaborates with healthcare professionals and research institutions to facilitate the development of new therapies and treatments. Leveraging a robust framework for clinical trial design and execution, Gonzalo Hernandez Martinez prioritizes patient safety and data integrity, ensuring that all studies adhere to rigorous regulatory standards. Through its strategic partnerships and commitment to scientific excellence, the sponsor aims to contribute significantly to the biomedical field and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toledo, Castilla La Mancha, Spain
Patients applied
Trial Officials
Gonzalo Hernandez
Study Chair
University Hospital Virgen de la Salud
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials